Fumiharu Ohka

List of Publications by Year
in descending order

52 papers	2,489 citations	361413 20 h-index	206112 48 g-index
52 all docs	52 docs citations	52 times ranked	5013 citing authors

#	Article	IF	Citations
1	Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas. Brain Tumor Pathology, 2022, 39, 14-24.	1.7	6
2	Supratotal Resection of Gliomas With Awake Brain Mapping: Maximal Tumor Resection Preserving Motor, Language, and Neurocognitive Functions. Frontiers in Neurology, 2022, 13, .	2.4	7
3	Recent Molecular and Genetic Findings in Intramedullary Spinal Cord Tumors. Neurospine, 2022, 19, 262-271.	2.9	6
4	Urinary MicroRNA-Based Diagnostic Model for Central Nervous System Tumors Using Nanowire Scaffolds. ACS Applied Materials & Interfaces, 2021, 13, 17316-17329.	8.0	27
5	Impact of the extent of resection on the survival of patients with grade II and III gliomas using awake brain mapping. Journal of Neuro-Oncology, 2021, 153, 361-372.	2.9	16
6	Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas. Cancer Research, 2021, 81, 4861-4873.	0.9	7
7	Driver Genetic Mutations in Spinal Cord Gliomas Direct the Degree of Functional Impairment in Tumor-Associated Spinal Cord Injury. Cells, 2021, 10, 2525.	4.1	6
8	Intraoperative seizure outcome of levetiracetam combined with perampanel therapy in patients with glioma undergoing awake brain surgery. Journal of Neurosurgery, 2021, 135, 998-1007.	1.6	3
9	Intraoperative <i>H3F3A K27M</i> Mutation-based Diagnosis of Spinal Cord Intramedullary Tumor. Spinal Surgery, 2021, 35, 215-217.	0.0	0
10	Genetic analysis in patients with newly diagnosed glioblastomas treated with interferon-beta plus temozolomide in comparison with temozolomide alone. Journal of Neuro-Oncology, 2020, 148, 17-27.	2.9	5
11	Neurocognitive and functional outcomes in patients with diffuse frontal lower-grade gliomas undergoing intraoperative awake brain mapping. Journal of Neurosurgery, 2020, 132, 1683-1691.	1.6	37
12	Spontaneous Tumor Regression of Intracranial Solitary Fibrous Tumor Originating From the Medulla Oblongata: A Case Report and Literature Review. World Neurosurgery, 2019, 130, 400-404.	1.3	6
13	Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma. Molecules, 2019, 24, 3046.	3.8	5
14	Pathogenic Epigenetic Consequences of Genetic Alterations in IDH-Wild-Type Diffuse Astrocytic Gliomas. Cancer Research, 2019, 79, 4814-4827.	0.9	6
15	Aberrant Active cis-Regulatory Elements Associated with Downregulation of RET Finger Protein Overcome Chemoresistance in Glioblastoma. Cell Reports, 2019, 26, 2274-2281.e5.	6.4	8
16	A novel high-sensitivity assay to detect a small fraction of mutant IDH1 using droplet digital PCR. Brain Tumor Pathology, 2018, 35, 97-105.	1.7	14
17	Neuroendoscopic Cylinder Surgery and 5-Aminolevulinic Acid Photodynamic Diagnosis of Deep-Seated Intracranial Lesions. World Neurosurgery, 2018, 116, e35-e41.	1.3	13
18	Immunohistochemical ATRX expression is not a surrogate for 1p19q codeletion. Brain Tumor Pathology, 2018, 35, 106-113.	1.7	16

#	Article	IF	Citations
19	Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro-Oncology, 2018, 20, 66-77.	1.2	225
20	Treatment of Primary CNS Lymphoma with RMPV (Rituximab, Methotrexate, Procarbazine, Vincristine) Therapy : Challenges and Prospects. Japanese Journal of Neurosurgery, 2018, 27, 29-36.	0.0	2
21	Characterization of Intraoperative Motor Evoked Potential Monitoring for Surgery of the Pediatric Population with Brain Tumors. World Neurosurgery, 2018, 119, e1052-e1059.	1.3	5
22	Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: A multi-institutional collaborative study. Radiotherapy and Oncology, 2018, 129, 347-351.	0.6	18
23	Supratotal Resection of Diffuse Frontal Lower Grade Gliomas with Awake Brain Mapping, Preserving Motor, Language, and Neurocognitive Functions. World Neurosurgery, 2018, 119, 30-39.	1.3	29
24	Significance of low mTORC1 activity in defining the characteristics of brain tumor stem cells. Neuro-Oncology, 2017, 19, now237.	1.2	6
25	A novel all-in-one intraoperative genotyping system for IDH1-mutant glioma. Brain Tumor Pathology, 2017, 34, 91-97.	1.7	16
26	Organotypic brain explant culture as a drug evaluation system for malignant brain tumors. Cancer Medicine, 2017, 6, 2635-2645.	2.8	24
27	Remote ischemic preconditioning protects human neural stem cells from oxidative stress. Apoptosis: an International Journal on Programmed Cell Death, 2017, 22, 1353-1361.	4.9	10
28	Significance of perivascular tumour cells defined by CD109 expression in progression of glioma. Journal of Pathology, 2017, 243, 468-480.	4.5	36
29	Negative impact of leukoaraiosis on the incidence of brain metastases in patients with lung cancer. Journal of Neuro-Oncology, 2017, 135, 299-306.	2.9	8
30	Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study. Anticancer Research, 2017, 37, 5215-5223.	1.1	10
31	LATS2 Positively Regulates Polycomb Repressive Complex 2. PLoS ONE, 2016, 11, e0158562.	2.5	8
32	Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities. Immunotherapy, 2016, 8, 1393-1404.	2.0	8
33	Targeting the Notch-regulated non-coding RNA TUG1 for glioma treatment. Nature Communications, 2016, 7, 13616.	12.8	267
34	Histone Deacetylase Inhibition in Prostate Cancer Triggers miR-320â€“Mediated Suppression of the Androgen Receptor. Cancer Research, 2016, 76, 4192-4204.	0.9	41
35	An immuno-wall microdevice exhibits rapid and sensitive detection of IDH1-R132H mutation specific to grade II and III gliomas. Science and Technology of Advanced Materials, 2016, 17, 618-625.	6.1	12
36	CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains. Cancer Immunology Research, 2016, 4, 259-268.	3.4	90

#	Article	IF	Citations
37	Rapid sensitive analysis ofIDH1mutation in lower-grade gliomas by automated genetic typing involving a quenching probe. Cancer Investigation, 2016, 34, 12-15.	1.3	6
38	Activation of Yes-Associated Protein in Low-Grade Meningiomas Is Regulated by Merlin, Cell Density, and Extracellular Matrix Stiffness. Journal of Neuropathology and Experimental Neurology, 2015, 74, 704-709.	1.7	14
39	Clinical Significance of Epigenetic Alterations in Glioblastoma. , 2015, , 339-350.		0
40	Aberrant TET1 Methylation Closely Associated with CpG Island Methylator Phenotype in Colorectal Cancer. Cancer Prevention Research, 2015, 8, 702-711.	1.5	47
41	Applicable advances in the molecular pathology of glioblastoma. Brain Tumor Pathology, 2015, 32, 153-162.	1.7	12
42	Mutational landscape and clonal architecture in grade II and III gliomas. Nature Genetics, 2015, 47, 458-468.	21.4	729
43	Assessment of Tumor Cells in a Mouse Model of Diffuse Infiltrative Glioma by Raman Spectroscopy. BioMed Research International, 2014, 2014, 1-8.	1.9	21
44	Peptide-based inhibition of the HOXA9/PBX interaction retards the growth of human meningioma. Cancer Chemotherapy and Pharmacology, 2014, 73, 53-60.	2.3	20
45	Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation. Tumor Biology, 2014, 35, 5911-5920.	1.8	95
46	Epigenetic dysregulation in glioma. Cancer Science, 2014, 105, 363-369.	3.9	58
47	Chromatin Regulator PRC2 Is a Key Regulator of Epigenetic Plasticity in Glioblastoma. Cancer Research, 2013, 73, 4559-4570.	0.9	91
48	A hypoxia-inducible factor (HIF)-3Î± splicing variant, HIF-3Î±4 impairs angiogenesis in hypervascular malignant meningiomas with epigenetically silenced HIF-3Î±4. Biochemical and Biophysical Research Communications, 2013, 433, 139-144.	2.1	29
49	Epigenetic subclassification of meningiomas based on genome-wide DNA methylation analyses. Carcinogenesis, 2012, 33, 436-441.	2.8	76
50	Current Trends in Targeted Therapies for Glioblastoma Multiforme. Neurology Research International, 2012, 2012, 1-13.	1.3	142
51	Contribution of MicroRNA-1275 to Claudin11 Protein Suppression via a Polycomb-mediated Silencing Mechanism in Human Glioma Stem-like Cells. Journal of Biological Chemistry, 2012, 287, 27396-27406.	3.4	51
52	The Global DNA Methylation Surrogate LINE-1 Methylation Is Correlated with MGMT Promoter Methylation and Is a Better Prognostic Factor for Glioma. PLoS ONE, 2011, 6, e23332.	2.5	95